← brief for 2026-08-26 · Slowing decline

PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.

Article No results yet Peer reviewed

Key takeaways

This is a short plain-language explainer about the SOUL trial, not the trial results themselves. SOUL tested semaglutide taken as a pill in people with type 2 diabetes who also had clogged arteries, kidney disease, or both. The piece describes what the trial was set up to look at. It reports no new numbers of its own.

Who did this work

Monroe RE · Marx N · McGuire DK

Source

Article · PubMed, the drug frontier · 2026 Aug 26
https://pubmed.ncbi.nlm.nih.gov/42647148/